13 April 2021 - A disparity in UK access to a medicine for Duchenne muscular dystrophy has been addressed, after Scotland gave a green light to use of PTC Therapeutics’ Translarna for the first time.

The Scottish Medicines Consortium says that Translarna (ataluren) can be provided by NHS Scotland for a period of three years, once PTC submits a plan detailing how further data on the effects of Translarna – including those on the patient and carer lived experience – will be collected.

Read Pharmaphorum article